5,611 reports of this reaction
3.3% of all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE reports
#14 most reported adverse reaction
ANHEDONIA is the #14 most commonly reported adverse reaction for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc. There are 5,611 FDA adverse event reports linking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE to ANHEDONIA. This represents approximately 3.3% of all 167,978 adverse event reports for this drug.
Patients taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE who experience anhedonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANHEDONIA is moderately reported among EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE users, representing a notable but not dominant share of adverse events.
In addition to anhedonia, the following adverse reactions have been reported for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE:
The following drugs have also been linked to anhedonia in FDA adverse event reports:
ANHEDONIA has been reported as an adverse event in 5,611 FDA reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANHEDONIA accounts for approximately 3.3% of all adverse event reports for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, making it a notable side effect.
If you experience anhedonia while taking EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.